A: The assay is primarily used in neurology and neurodegeneration research to quantify neurofilament light (NfL), a well-established biomarker of axonal damage. Researchers use this assay to study disease progression, treatment response, and neuronal injury across a range of conditions, including Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and traumatic brain injury (TBI).

A: The assay is validated for use with human serum, plasma (EDTA), and CSF, as well as mouse serum. It allows researchers to compare data across sample types without sacrificing accuracy or sensitivity.

A: The Quanterix Simoa® NfL assay uses Quanterix’s Simoa® digital immunoassay technology, which provides higher sensitivity, a broad dynamic range, and greater reproducibility compared to standard ELISAs and other immunoassays. It supports both research and clinical development applications.